Literature DB >> 16096102

Genomic medicine: genetic variation and its impact on the future of health care.

Huntington F Willard1, Misha Angrist, Geoffrey S Ginsburg.   

Abstract

Advances in genome technology and other fruits of the Human Genome Project are playing a growing role in the delivery of health care. With the development of new technologies and opportunities for large-scale analysis of the genome, transcriptome, proteome and metabolome, the genome sciences are poised to have a profound impact on clinical medicine. Cancer prognostics will be among the first major test cases for a genomic medicine paradigm, given that all cancer is caused by genomic instability, and microarrays allow assessment of patients' entire expressed genomes. Analysis of breast cancer patients' expression patterns can already be highly correlated with recurrence risks. By integrating clinical data with gene expression profiles, imaging, metabolomic profiles and proteomic data, the prospect for developing truly individualized care becomes ever more real. Notwithstanding these promises, daunting challenges remain for genomic medicine. Success will require planning robust prospective trials, analysing health care economic and outcome data, assuaging insurance and privacy concerns, developing health delivery models that are commercially viable and scaling up to meet the needs of the whole population.

Entities:  

Mesh:

Year:  2005        PMID: 16096102      PMCID: PMC1569521          DOI: 10.1098/rstb.2005.1683

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  76 in total

1.  The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations.

Authors:  E S Collie-Duguid; S C Pritchard; R H Powrie; J Sludden; D A Collier; T Li; H L McLeod
Journal:  Pharmacogenetics       Date:  1999-02

2.  Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics.

Authors:  Melissa A Burns; Wenlei He; Chin-Lee Wu; Leo L Cheng
Journal:  Technol Cancer Res Treat       Date:  2004-12

3.  Excess in the pharmaceutical industry.

Authors:  Marcia Angell
Journal:  CMAJ       Date:  2004-12-07       Impact factor: 8.262

4.  Consumers' use of the Internet for health insurance.

Authors:  M Kate Bundorf; Sara J Singer; Todd H Wagner; Laurence Baker
Journal:  Am J Manag Care       Date:  2004-09       Impact factor: 2.229

5.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Authors:  J Lazarou; B H Pomeranz; P N Corey
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

Review 6.  The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine.

Authors:  K G Van Scoik; C A Johnson; W R Porter
Journal:  Drug Metab Rev       Date:  1985       Impact factor: 4.518

Review 7.  Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice.

Authors:  Carlos J Cara; Amado Salvador Pena; Miquel Sans; Luis Rodrigo; Mercedes Guerrero-Esteo; Joaquín Hinojosa; Julio García-Paredes; Luis G Guijarro
Journal:  Med Sci Monit       Date:  2004-10-26

Review 8.  Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1.

Authors:  George A Kenna; John E McGeary; Robert M Swift
Journal:  Am J Health Syst Pharm       Date:  2004-11-01       Impact factor: 2.637

Review 9.  Genomic and proteomic technologies for individualisation and improvement of cancer treatment.

Authors:  Julia Wulfkuhle; Virginia Espina; Lance Liotta; Emanuel Petricoin
Journal:  Eur J Cancer       Date:  2004-11       Impact factor: 9.162

10.  Database resources of the National Center for Biotechnology Information.

Authors:  David L Wheeler; Tanya Barrett; Dennis A Benson; Stephen H Bryant; Kathi Canese; Deanna M Church; Michael DiCuccio; Ron Edgar; Scott Federhen; Wolfgang Helmberg; David L Kenton; Oleg Khovayko; David J Lipman; Thomas L Madden; Donna R Maglott; James Ostell; Joan U Pontius; Kim D Pruitt; Gregory D Schuler; Lynn M Schriml; Edwin Sequeira; Steven T Sherry; Karl Sirotkin; Grigory Starchenko; Tugba O Suzek; Roman Tatusov; Tatiana A Tatusova; Lukas Wagner; Eugene Yaschenko
Journal:  Nucleic Acids Res       Date:  2005-01-01       Impact factor: 16.971

View more
  16 in total

1.  Transforming the practice of medicine using genomics.

Authors:  Geoffrey S Ginsburg; Geoffrey S Ginsburg; Jeanette J McCarthy
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

2.  Personal genomics and individual identities: motivations and moral imperatives of early users.

Authors:  Michelle L McGowan; Jennifer R Fishman; Marcie A Lambrix
Journal:  New Genet Soc       Date:  2010-09-01

3.  Introduction: genetic variation and human health.

Authors:  M P H Stumpf; D B Goldstein; N W Wood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

4.  Medical genetics in the genomic medicine of the 21st century.

Authors:  Charles J Epstein
Journal:  Am J Hum Genet       Date:  2006-09       Impact factor: 11.025

5.  Paying for personalized care: cancer biomarkers and comparative effectiveness.

Authors:  Rahber Thariani; David L Veenstra; Josh J Carlson; Louis P Garrison; Scott Ramsey
Journal:  Mol Oncol       Date:  2012-03-06       Impact factor: 6.603

6.  Personalised medicine: a critique on the future of health care.

Authors:  Jacqueline Savard
Journal:  J Bioeth Inq       Date:  2013-03-21       Impact factor: 1.352

7.  The 'thousand-dollar genome': an ethical exploration.

Authors:  Wybo J Dondorp; Guido M W R de Wert
Journal:  Eur J Hum Genet       Date:  2013-06       Impact factor: 4.246

Review 8.  Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond.

Authors:  N J Schork; K Nazor
Journal:  Adv Genet       Date:  2017-07-25       Impact factor: 1.944

Review 9.  De novo vs. inherited copy number variations in multiple sclerosis susceptibility.

Authors:  Kalthoum Tizaoui
Journal:  Cell Mol Immunol       Date:  2018-02-12       Impact factor: 11.530

10.  Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer.

Authors:  Luis Parodi; Eve Pickering; Laura A Cisar; Doug Lee; Raoudha Soufi-Mahjoubi
Journal:  Arch Drug Inf       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.